Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07581613

A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration in Adult Periodontitis Patients

The goal of this clinical trial is to learn if a novel peptide-rich hydrogel works to achieve periodontal regeneration in adults. It will also learn about the safety of the hydrogel. The main questions it aims to answer are:

* Does the novel peptide hydrogel achieve periodontal regeneration to a similar degree as another currently used therapy (hyaluronic acid)? * What medical problems, if any, do participants have when receiving the novel hydrogel treatment? Researchers will compare the novel peptide hydrogel to another commonly used hydrogel (hyaluronic acid) to see if the peptide hydrogel works to treat periodontal bone defects.

Participants will:

* Receive the novel hydorgel or hyaluronic acid when they undergo periodontal regenerative surgery * Visit the clinic at regular intervals for 1 year after the surgery for follow ups

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Faculty of Dentistry, University of Oslo, Oslo, Norway

Loading trial locations.

About this study

The primary objective of this study (PICOS) is to compare, in adult periodontitis patients (P), the efficacy of a P-HA hydrogel (PeriHeal) (I) to that of a commercial HA hydrogel (hyaDENT BG) (C) for the regenerative treatment of intrabony defects based on CAL changes (O) after 6 and 12 months in a RCT (S).

Additional objectives are to assess (a) changes in secondary clinical and radiographic outcomes, (b) patient-reported outcomes (PROs), and (c) molecular outcomes based on proteomic analysis of gingival crevicular fluid (GCF) (see details below).

The null hypothesis (H0) is that there are no statistically significant differences between P-HA and HA hydrogels in terms of CAL after 6 and 12 months.

The primary outcome is CAL change 6 and 12 months after regenerative surgery. Secondary outcomes measured 6 and 12 months after regenerative surgery include changes in: probing pocket depth (PPD), bleeding on probing (BoP), recession (REC), and MBL. Post-operative wound healing and patient-reported symptoms will be assessed 7 and 14 days after surgery. Patients' oral health-related quality of life (OHRQoL) will be assessed at baseline and 6 and 12 months after surgery. GCF collected at 7, 14 and 30 days after surgery will be analysed using mass spectrometry-based proteomics.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults >18 years with periodontitis (Stage III or IV)
  • Systemically healthy (ASA I or II)
  • Non-smokers or smoking <10 cigarettes/day
  • Having undergone steps 1 (risk factor control, oral hygiene improvement including interdental hygiene) and 2 (subgingival instrumentation and biofilm control) of systematic periodontal therapy
  • Indication for step 3 periodontal therapy, i.e., sites with residual/persistent pockets (PPD >5 mm and BoP or PPD >6 mm) around single- or multi-rooted teeth with mobility <grade II at re-evaluation 8-12 weeks after non-surgical instrumentation (Step 2). Further site-specific criteria include at least one site with a radiographic infrabony defect (2- or 3-walled) with a >3 mm intrabony component, not associated with an open furcation, indicated for regenerative surgery
  • Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) ≤20% before surgery

Exclusion criteria

  • Medical conditions contraindicating surgery
  • Pregnancy or lactation
  • Current use of systemic antibiotics
  • Smoking >10 cigarettes/day
  • FMPS or FMBS >20%
  • Mobility grade II or greater
  • Acute oral infections, active endo-perio lesions or active carious lesions on teeth associated with bone defects

Treatment and study plan

Hydrogel

Biological

A novel cross-linked HA hydrogel incorporating proline-rich peptides (PeriHeal, Corticalis AS, Oslo, Norway) has been developed to enhance periodontal wound healing and regeneration.

Other names: Proline-rich peptide hydrogel

Primary outcomes

  1. CAL change

    Time frame: 6 and 12 months after periodontal regenerative surgery

    Changes in Clinical Attachment Level (CAL) of the treated teeth

Secondary outcomes

  1. MBL change

    Time frame: 6 and 12 months after regenerative periodontal surgery

    Changes in radiographic Marginal Bone Level (MBL)

  2. Gingival Healing Index (GHI)

    Time frame: 7 and 14 days after periodontal regenerative surgery

    GHI is used to assess the postsurgery conditions of the interdental papilla based on severity of wound dehiscence: score 3: no wound dehiscence and complete flap closure, score 2: minor wound dehiscence with loss of interdental soft tissue limited to the papillary tip; score 1: major wound dehiscence with incomplete flap closure.

  3. Oral health related quality of life

    Time frame: 6 and 12 months after regenerative surgery

    Oral health related quality of life will be assessed using the Oral Health Impact Profile-14 (OHIP-14) instrument which assesses quality of life based on 14 questions under the following domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. The scale ranges from 0 to 14 with a higher score indicating a worse outcome.

  4. Proteomic analysis of gingival crevicular fluid (GCF)

    Time frame: 7, 14 and 30 days after regenerative surgery

    Proteomic analysis of GCF from the treated teeth using liquid chromatography mass spectrometry (LC-MS) which semi-quantitatively analyses the total number and type (names and IDs) of proteins present in GCF obtained from the test and control sites.

Study contacts

Contact information is provided by the study sponsor or research team.

Anders Verket, Ph.D.

CONTACT

[email protected]

+4722852064

Siddharth V Shanbhag, Ph.D.

CONTACT

[email protected]

+4740041647

Sponsors and collaborators

Lead sponsor

Siddharth Shanbhag

Other

Collaborators

  • Universidad Complutense de Madrid

Registry information

Official study title

A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration: a Multicenter Parallel-arm Randomized Clinical Trial

Acronym: PERIHEAL

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
May 12, 2026
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.